Please ensure Javascript is enabled for purposes of website accessibility

Biogen Loses Patent Case Over Its Best-Selling Drug

By Todd Campbell – Updated Jun 22, 2020 at 6:17PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A judge has ruled in favor of Mylan's challenge to Tecfidera's patent protection.

Biogen's (BIIB 1.04%) Tecfidera is one of the world's best-selling multiple sclerosis drugs, and on Thursday, a judge in the Northern District of West Virginia ruled that a key patent on it is invalid. The decision means that Mylan (MYL), the plaintiff in the suit, will be able to launch a generic version of the drug, which last year accounted for $4.4 billion of Biogen's $14.4 billion in revenue.

A gavel resting on a desk.

IMAGE SOURCE: GETTY IMAGES.

Tecfidera is a twice-daily oral drug prescribed to reduce the number and severity of MS relapses. Patent '514, which was just invalidated, would have protected it from generic competition until 2028.

When Mylan sued Biogen, it asserted that "a lack of written description" should result in the patent being rescinded. According to Reuters, Judge Irene Keeley agreed, finding that the biotech company didn't "adequately describe the claimed invention."

The ruling doesn't mean MS patients will be able to buy a generic formulation yet, though. The decision could be overturned in the appeal Biogen has already said it will file. The appeals process could take up to a year, and in the meantime, Biogen also plans to ask for an emergency order to prevent Mylan from launching a generic version of the drug while litigation continues.

Nevertheless, the West Virginia court's decision suggests that a similar challenge advancing in Delaware could also go against Biogen. If so, a generic version of Tecfidera could become available by the middle of next year, according to Umer Raffat, an analyst at Evercore ISI.

Todd Campbell owns shares of Mylan. The Motley Fool owns shares of and recommends Biogen. The Motley Fool recommends Mylan. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Biogen Inc. Stock Quote
Biogen Inc.
BIIB
$197.79 (1.04%) $2.04
Viatris Inc. Stock Quote
Viatris Inc.
MYL

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
327%
 
S&P 500 Returns
105%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.